Tubulis GmbH

Our CEO Dominik Schumacher recently had the pleasure to welcome Philip Hemme to our office in Munich, where they recorded a new Flot.bio #podcast episode. They discussed opportunities and challenges #biotech founders are facing, how to successfully scale a company and securing the necessary funding on the way, and of course also the future of #ADCs, our favorite drug class. Thank you for the great exchange, Philip! Stay tuned for the full-length podcast episode, which will be available soon!

Shortly after announcing the dosing of our first patient, we received Fast Track designation by the FDA for TUB-040 in platinum-resistant ovarian cancer (OC). OC is the leading cause of death among women diagnosed with gynecological cancers, and nearly all patients who don't respond to platinum therapies will sooner or later develop resistance. Once resistant, outcomes are poor with a median survival of less than 16 months, leaving patients in desperate need of new treatment options. The Fast Track status granted by the FDA brings us one step closer to our goal of bringing the true value of ADCs to patients and will allow us to accelerate the development of TUB-040.   Read the full press release here: https://bit.ly/3RLXGNE For more information on our clinical trial or technology visit https://lnkd.in/dMpvdaSw or www.tubulis.com

Thank you Clarivate for Life Sciences & Healthcare for selecting us as an #ADC company to watch and featuring us in your comprehensive overview of the ADC space. The report highlights the different approaches to developing ADCs, their unique characteristics and the technological advances that fuel innovation. At Tubulis GmbH, we create uniquely matched ADCs with superior biophysical properties. By combining novel proprietary technologies and disease-specific biological insights our goal is to deliver better outcomes for solid tumor patients.   Looking to learn more about Tubulis? Read the report below or visit https://tubulis.com/

With the IND approval from the FDA, we dosed our first patient in the US today in our Phase I/IIa study, NAPISTAR 1-01. Entering the clinic with our first candidate from our growing pipeline of next-generation #ADCs marks an important milestone for Tubulis and we look forward to bringing the true value of ADCs to patients with solid tumors.   The first-in-human trial is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-040, one of our lead candidates, as a monotherapy in patients with platinum-resistant, high-grade #OvarianCancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (#NSCLC), who have exhausted all other available treatment options. TUB-040 is a topoisomerase-I-based ADC targeting NaPi2b, which showed superior biophysical properties in preclinical studies indicating a high potential to improve efficient long-term anti-tumor responses.   Find the full press release here: https://bit.ly/3Xydc3K. If you want to read more on our proprietary suite of platform technologies and vision to usher in a new ADC era for better patient outcomes at www.tubulis.com

We are honored to be the recipient of "The Emerging Star Award" at the European Mediscience Awards 2024. We sincerely thank the organizers and the jury for recognizing the potential of Tubulis, an achievement that reflects our ongoing commitment to overcoming the key limitations of current #ADC technologies.   We also want to thank our whole team for their hard work and dedication. Together, we have translated our deep scientific expertise into a broad suite of proprietary technologies that enable the combination of novel #tumor targets and previously inaccessible payloads in a safe and efficient way, aiming to bring the true potential of ADCs to #patients in need.   Learn more about our mission and uniquely matched pipeline candidates at www.tubulis.com.   #Emergingstar #EMA24

Our CEO, Dominik Schumacher, and Ingo Lehrke, our CBO, are looking forward to participating in the upcoming J.P. Morgan European #Healthcare Forum on June 20th in London, where they will connect with key players in the #biotech and financial community. If you also happen to be in London, take the opportunity to discuss how we aim to realize the full therapeutic potential of #ADCs, our latest positive #pipeline data and upcoming developments at Tubulis, including the start of our first #ClinicalTrial in #SolidTumors just ahead. Send a direct message to Ingo here on LinkedIn to schedule a meeting on-site.   For further information around our unique suite of #ADC technologies and pipeline candidates, visit www.tubulis.com

  Meet our VP Chemistry, Marc-André Kasper, at the Chemical Protein Synthesis Meeting in Nagoya. https://cpsnagoya.ethz.ch/ Marc has been invited to share our recent advancements in antibody conjugation technology that we are leveraging to develop the next generation of #ADCs. Don’t miss his talk on Wednesday, June 5 at 11:30 JST.

Our colleagues Ingo Lehrke, CBO, and Jonas Helma-Smets, CSO, are looking forward to participating in the upcoming #BIO2024 Convention, starting next week in #SanDiego. If you want to discuss the future in #ADC development and learn more about our suite of trailblazing technologies to generate uniquely matched, indication-specific ADCs, with the start of our first #ClinicalTrial just ahead, reach out to us via the partnering system for a 1:1 meeting. For an overview of our platforms, pipeline candidates and #SolidTumor target indications, visit www.tubulis.com. 

Meet our #clinical development team at the upcoming #ASCO24 conference from May 31 to June 4, 2024, in #Chicago! Are you interested to learn more about our proprietary suite of unique #ADC technologies and target #SolidTumor indications, want to deep-dive into our promising efficacy & safety data for lead candidates TUB-030 and TUB-040, or get an introduction to the designs and protocol requirements of our soon-to-start #ClinicalTrials? Join us at our #booth 27123 in exhibition hall A to learn more and have a chat with our on-site team: Günter Fingerle-Rowson, CMO, Bjoern Hock, CDO, Mary Ann Lumiqued, VP Program Management, giovanni selvaggi, Consultant Clinical Development, and Inês Vasconcelos, Medical Director. If you’d like to book a 1:1 meeting with us, please use the following link: https://bit.ly/3UUmZOj Not in Chicago? Learn more about our revolutionary approach to usher in a new ADC era for better #patient outcomes at www.tubulis.com.

Meet our Discovery Scientist, Jan G. Felber, at the opening of the Centre for Targeted Protein Degradation #TPDinFocus starting on Monday in Dundee. Jan will show recent data from our Discovery project portfolio and outline how we expand our toolset of proprietary technologies to unlock novel powerful payloads for highly stable and efficient #ADCs beyond our two lead candidates TUB-030 and TUB-040. Poster Title: Degrader-ADCs unlock heterobifunctional degraders through mAb-like pharmacokinetics and excellent in vivo efficacy Find the agenda details here https://lnkd.in/exYTxNJd and learn more about our platform technologies and #SolidTumor pipeline candidates at www.tubulis.com